Respiratory physician Lutz Beckert considers chronic obstructive pulmonary disease management, including the prevention of COPD, the importance of smoking cessation and pulmonary rehabilitation, and the lifesaving potential of addressing treatable traits. He also discusses the logic of inhaler therapy, moving from single therapy to dual and triple therapy when indicated, as well as other aspects of management
Vigorous LDL cholesterol targets now set for secondary prevention of CVD
+Practice
In print
HEARTBEAT
Vigorous LDL cholesterol targets now set for secondary prevention of CVD
Wednesday 2 March 2022, 12:45 AM

ECG: Supplied
Consultant cardiologist Chris Ellis discusses the recent funding of rosuvastatin, focusing on its use for secondary prevention of cardiovascular disease
Key points, Rosuvastatin 40mg will lower the LDL cholesterol level by approximately 63 per cent, compared with about 55 per cent with atorvastatin 80mg.
Ezetimi, Pract Green w Pale Yellow
Kia ora and welcome to New Zealand Doctor Rata Aotearoa
Not a subscriber? Unlock this article by subscribing here.
References
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):11188.